Last $6.01 USD
Change Today +0.15 / 2.56%
Volume 135.1K
NBS On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/13/13 - $9.89
52 Week Low
05/9/14 - $4.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc. develops cell based therapeutics. The company is involved in the manufacture of cell therapy-based products; and provides product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. It also offers contract development and manufacturing services to clients advancing in the regenerative medicine industry; and collects, processes, and stores umbilical cord blood units and adult stem cells. The company is developing AMR-001, an autologous adult stem cell product to treat damaged heart muscle following an acute myocardial infarction. In addition, it develops T regulatory cell based therapeutics to treat diseases caused by imbalances in the immune system; and researches and develops therapeutics based on very small embryonic-like technology. The company has a collaboration agreement with Becton-Dickinson. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $945.0K
Chief Financial Officer and Vice President
Total Annual Compensation: $190.6K
President of Progenitor Cell Therapy, LLC and...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

Neostem, Inc. Appoints Steven M. Klosk as Independent Member of Board of Directors

Effective as of July 8, 2014, Neostem, Inc. appointed Steven M. Klosk, age 57, to serve as an independent member of the company's board of directors. Since 2008, Mr. Klosk has served as President, CEO & Director at Cambrex Corporation. In his current role, he is responsible for all aspects of Cambrex’s global business with manufacturing and R&D facilities in the US, Sweden, Italy, Estonia, Germany and India. Mr. Klosk has also held other executive positions at Cambrex Corporation, including Executive Vice President & COO; as well as President, Pharma Business Unit from 2007 through 2008, which encompassed four operating units in North America and Europe.

Neostem, Inc.(NasdaqCM:NBS) added to Russell 2000 Index

Neostem, Inc. will be added to the Russell 2000 Index.

Neostem, Inc.(NasdaqCM:NBS) added to Russell 3000 Index

Neostem, Inc. will be added to the Russell 3000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $6.01 USD +0.15

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $0.08 USD +0.0002
Athersys Inc $1.71 USD +0.02
BioTime Inc $2.70 USD +0.05
Cytori Therapeutics Inc $2.22 USD +0.01
Fibrocell Science Inc $3.22 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.4x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at